Sunnie Kim, MD
Associate Professor, Medicine-Medical Oncology
Medical School:
Department: Medicine-Medical Oncology
- MD, Columbia University College of Physicians and Surgeons (2009)
- BA, Columbia University (NY) (2002)
- New York University School of Medicine Program, Internal Medicine (2012)
- New York Presbyterian Hospital (Cornell Campus) Program, Hematology and Oncology (2016)
Department: Medicine-Medical Oncology
Professional Titles
- Associate Professor
Publications
- Kim S. The role of antiangiogenesis agents in refractory metastatic colorectal cancer. Clin Adv Hematol Oncol. 2023 Apr;21(4):209-212. PubMed PMID: 37039731
- Catenacci DV, Kang YK, Uronis HE, Lee KW, Ng MC, Enzinger PC, Park SH, Gold PJ, Lacy J, Hochster HS, Oh SC, Kim YH, Marrone KA, Kelly RJ, Juergens RA, Kim JG, Alcindor T, Sym SJ, Song EK, Chee CE, Chao Y, Kim S, Oh DY, Yen J, Odegaard JI, Lagow E, Li D, Sun J, Kaminker P, Moore PA, Rosales MK, Park H. Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma. Oncology (Williston Park). 2023 Apr 25;37(4):176-183. PubMed PMID: 37104758
- Pandey A, Lieu CH, Kim SS. The Local Microbiome in Esophageal Cancer and Treatment Response: A Review of Emerging Data and Future Directions. Cancers (Basel). 2023 Jul 10;15(14). PubMed PMID: 37509225
- Cerniglia M, Klepadlo M, Sheneman D, Kim SS. Response to PD-1 inhibitor after progression on PD-L1 inhibitor in advanced HCC. BMJ Case Rep. 2022 Aug 12;15(8). PubMed PMID: 35961684
- Redman JM, Tsai YT, Weinberg BA, Donahue RN, Gandhy S, Gatti-Mays ME, Abdul Sater H, Bilusic M, Cordes LM, Steinberg SM, Marte JL, Jochems C, Kim SS, Marshall JL, McMahon S, Redmond E, Schlom J, Gulley JL, Strauss J. A Randomized Phase II Trial of mFOLFOX6 Bevacizumab Alone or with AdCEA Vaccine Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer. Oncologist. 2022 Mar 11;27(3):198-209. PubMed PMID: 35274710
- Cerniglia M, Xiu J, Grothey A, Pishvaian MJ, Baca Y, Hwang JJ, Marshall JL, VanderWalde AM, Shields AF, Lenz HJ, Korn WM, Salem M, Philip PA, Goldberg RM, Zeng J, Kim SS. Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers. Mol Cancer Ther. 2022 Jan;21(1):227-236. PubMed PMID: 34725190
- Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, Farjah F, Gerdes H, Gibson MK, Hochwald S, Hofstetter WL, Ilson DH, Keswani RN, Kim S, Kleinberg LR, Klempner SJ, Lacy J, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Outlaw D, Park H, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian N, Pluchino LA. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 Feb;20(2):167-192. PubMed PMID: 35130500
- Ho F, Torphy RJ, Friedman C, Leong S, Kim S, Wani S, Schefter T, Scott CD, Mitchell JD, Weyant MJ, Meguid RA, Gleisner AL, Goodman KA, McCarter MD. Induction Chemotherapy Plus Neoadjuvant Chemoradiation for Esophageal and Gastroesophageal Junction Adenocarcinoma. Ann Surg Oncol. 2021 Nov;28(12):7208-7218. PubMed PMID: 33884489
- Pedersen KS, Foster NR, Overman MJ, Boland PM, Kim SS, Arrambide KA, Jaszewski BL, Bekaii-Saab T, Graham RP, Welch J, Wilson RH, McWilliams RR. ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma. Clin Cancer Res. 2021 Jul 1;27(13):3641-3648. PubMed PMID: 33883178
- Burke AM, Yeh C, Kim S, Bergquist P, Krishnan P, Barac A, Srichai MB, Unger K. A Prospective Study of Early Radiation Associated Cardiac Toxicity Following Neoadjuvant Chemoradiation for Distal Esophageal Cancer. Front Oncol. 2020;10:1169. PubMed PMID: 32903617
- Pishvaian MJ, Wang H, He AR, Hwang JJ, Smaglo BG, Kim SS, Weinberg BA, Weiner LM, Marshall JL, Brody JR. A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. Clin Cancer Res. 2020 Oct 1;26(19):5092-5101. PubMed PMID: 32669374
- Catenacci DVT, Kang YK, Park H, Uronis HE, Lee KW, Ng MCH, Enzinger PC, Park SH, Gold PJ, Lacy J, Hochster HS, Oh SC, Kim YH, Marrone KA, Kelly RJ, Juergens RA, Kim JG, Bendell JC, Alcindor T, Sym SJ, Song EK, Chee CE, Chao Y, Kim S, Lockhart AC, Knutson KL, Yen J, Franovic A, Nordstrom JL, Li D, Wigginton J, Davidson-Moncada JK, Rosales MK, Bang YJ. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. Lancet Oncol. 2020 Aug;21(8):1066-1076. PubMed PMID: 32653053
- Villano AM, Zeymo A, McDermott J, Crocker A, Zeck J, Chan KS, Shara N, Kim S, Al-Refaie WB. Evaluating Dissemination of Adequate Lymphadenectomy for Gastric Cancer in the USA. J Gastrointest Surg. 2019 Nov;23(11):2119-2128. PubMed PMID: 30788715
- Kim S, Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Ung B, Parisi M, Marshall JL. Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States. Adv Ther. 2018 Oct;35(10):1564-1577. PubMed PMID: 30209750
- Choe HK, De Sancho MT, Kim SS, Dai T, Shah MA. Low molecular weight heparin versus rivaroxaban in the treatment of venous thromboembolism in gastrointestinal malignancies. Blood Coagul Fibrinolysis. 2018 Mar;29(2):227-230. PubMed PMID: 29389673
- Kim S, Abou-Alfa GK. The role of tyrosine kinase inhibitors in hepatocellular carcinoma. Clin Adv Hematol Oncol. 2014 Jan;12(1):36-41. PubMed PMID: 25000314
- Wan DW, Tzimas D, Smith JA, Kim S, Araujo J, David R, Lobach I, Sarpel U. Risk factors for early-onset and late-onset hepatocellular carcinoma in Asian immigrants with hepatitis B in the United States. Am J Gastroenterol. 2011 Nov;106(11):1994-2000. PubMed PMID: 21912436
Practice Locations
University of Colorado Cancer Center - Anschutz Medical Campus
1665 Aurora Ct
Aurora, CO 80045
720-848-0300
UCHealth Anschutz Outpatient Pavilion - Anschutz Medical Campus
1635 Aurora Ct
Aurora, CO 80045
720-848-0000
UCHealth University of Colorado Hospital (UCH)
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000
Pancreas & Biliary Multidisciplinary Clinic - Anschutz
1665 Aurora Ct
3rd Floor
Aurora, CO 80045
1-855-824-7262
Hospital Affiliation
1665 Aurora Ct
Aurora, CO 80045
720-848-0300
UCHealth Anschutz Outpatient Pavilion - Anschutz Medical Campus
1635 Aurora Ct
Aurora, CO 80045
720-848-0000
UCHealth University of Colorado Hospital (UCH)
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000
Pancreas & Biliary Multidisciplinary Clinic - Anschutz
1665 Aurora Ct
3rd Floor
Aurora, CO 80045
1-855-824-7262
Hospital Affiliation
- University of Colorado Hospital
Specialty Information
Specialties
- Internal Medicine, Board Certification (2012)
- Medical Oncology, Board Certification (2016)
- Cancers - Anal Cancer
- Cancers
- Cancers - Biliary Cancer
- Cancers - Colorectal Cancer
- Cancers - Gastroenterologic Cancer (Colon, Stomach, Esophageal, Liver)
- Cancers - Pancreatic Cancer
Clinical Interests
Gastrointestinal Medical Oncology
Care Philosophy
I strive to provide patients with individualized care after careful and thoughtful discussion. I strongly believe that my job is to present all options to patients so that we can make the best possible treatment decisions, together. To that end, I am dedicated to contributing to the field by leading research to advance our understanding of gastrointestinal cancers to uncover more effective treatment options. I serve as the Principal Investigator on multiple investigator initiated and industry sponsored clinical trials. I also sit on several national committees including National Comprehensive Cancer Network (NCCN) Gastric and Esophageal Cancers Guidelines and American Society of Clinical Oncology (ASCO) Evidence Based Medicine Committee.
Gastrointestinal Medical Oncology
Care Philosophy
I strive to provide patients with individualized care after careful and thoughtful discussion. I strongly believe that my job is to present all options to patients so that we can make the best possible treatment decisions, together. To that end, I am dedicated to contributing to the field by leading research to advance our understanding of gastrointestinal cancers to uncover more effective treatment options. I serve as the Principal Investigator on multiple investigator initiated and industry sponsored clinical trials. I also sit on several national committees including National Comprehensive Cancer Network (NCCN) Gastric and Esophageal Cancers Guidelines and American Society of Clinical Oncology (ASCO) Evidence Based Medicine Committee.
General Information
Medical Schools:
- MD, Columbia University College of Physicians and Surgeons (2009)
Undergraduate Schools:
- BA, Columbia University (NY) (2002)
Residency Programs:
- New York University School of Medicine Program, Internal Medicine (2012)
Fellowships:
- New York Presbyterian Hospital (Cornell Campus) Program, Hematology and Oncology (2016)
Department: Medicine-Medical Oncology